Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy

被引：37

作者：

Patriti, Alberto ^{[1
]}

Cavazzoni, Emanuel ^{[1
]}

Graziosi, Luigina ^{[1
]}

Pisciaroli, Antonio ^{[1
]}

Luzi, Debora ^{[1
]}

Gulla, Nino ^{[1
]}

Donini, Annibale ^{[1
]}

机构：

[1] Univ Perugia, Dept Clin & Expt Med, Sect Internal Med & Oncol Sci, I-06156 Perugia, Italy

来源：

SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES | 2008年 / 18卷 / 04期

关键词：

peritoneal carcinosis; mesothelioma; HIPEC; laparoscopic; intraoperative; chemotherapy; hyperthermic; surgery; oncologic; oncology; ascites; malignant ascites;

D O I：

10.1097/SLE.0b013e318173a61e

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

A variety of options have been proposed to treat malignant ascites but most of them have failed to reach a significant impact in terms of palliation. Laparoscopic hyperthermic intraperitoneal chemotherapy (LHIPEC) Could represent a good therapeutic tool for patients in whom medical therapies have failed and peritoneovenous Shunting is contraindicated. Here we present a case of a 49-year-old woman with malignant ascites secondary to peritoneal spreading of a right pleural mesothelioma. After failure of medical therapy, the patient underwent LHIPEC with Cisplatin 25mg/m(2)/L and Doxorubicin 7 mg/m(2)/L. A dramatic reduction of ascites was documented in the postoperative period and the patient experienced complete abdominal symptom relief. Ascites did not recur during a follow-up period of 6 months. LHIPEC Could be a good therapeutic option to palliate malignant ascites from mesothelioma in cases not eligible for a radical treatment. Further studies are needed to standardize dosage and perfusion parameters.

引用

页码：426 / 428

页数：3